Navigation Links
NuView Life Sciences and Thomas Jefferson University Sign Agreement for Exclusive Development and Commercialization Rights to Novel Prostate Cancer Diagnostic
Date:3/26/2013

Park City, UT (PRWEB) March 26, 2013

NuView Life Sciences (NLS), a privately-held company developing next generation imaging and in vitro diagnostic biomarkers with the ability to identify and locate disease at the earliest stages of development, today announced it has entered into an agreement with Thomas Jefferson University for exclusive development and commercialization rights to a novel urine screen for the early detection of Prostate and Bladder Cancer.

“We are excited to add this technology into the NuView Portfolio. This in vitro diagnostic is an excellent complement to our diagnostic imaging biomarkers in development,” stated Brian Dowd, Ph.D., Vice President of Clinical and Scientific Affairs at NLS. “Early and accurate detection of Prostate and Bladder Cancer should result in a significant reduction of invasive biopsy procedures and increase the probability for successful treatment outcomes in patients.”

This novel in vitro diagnostic (IVD) detects minute quantities of cancer cells shed into the urinary tract by measuring the expression of the vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide receptor-1 (VPAC1) receptor. To date, the technology has displayed impressive sensitivity and specificity for the identification of Prostate and Bladder Cancer in human urine samples.

Previous work by Mathew Thakur, Ph.D., academic collaborator, Professor Radiology and Director of Radiopharmaceutical Research and Molecular Imaging at Thomas Jefferson University (TJU), Philadelphia, has shown Prostate Cancer cells express the oncogene product VPAC1 in high density on their cell surface. This occurs at a very early stage in oncogenic transformation, well before cell morphology alterations for histologic confirmation, and even well before the elevation of Prostate Specific Antigen (PSA). NuView is also developing NLS-VPAC1, a positron emission tomography (PET)-based imaging
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Positive Clinical Breast Cancer Data Presented for NuView’s Molecular Imaging Biomarker NLS-VPAC1
2. Digital Science & SciBite Join Forces to Harness Big Data for Life Sciences
3. VG Life Sciences, Inc. Secures Two-Year Funding Commitment and Administrative Support from MedBridge, LLC
4. RoviSys Partners with POMS MES to Expand Life Sciences Capabilities
5. Best Practices for Lean Six Sigma in Clinical Development and R&D, New Xtalks Life Sciences Webinar
6. A “Fail Fast” Strategy for Lead Optimization Pharmacology and Toxicology, New Xtalks Life Sciences Webinar
7. Life Sciences Technology Conference and Career Fair on March 26th in Raleigh, NC
8. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
9. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
10. Lockheed Martin to Continue Providing Life Sciences Support to NASA
11. Nasseo Wins CONNECT Life Sciences Capital Competition and Joins CONNECT Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled ... 2pm EST (11am PST), “Natural Language Processing: Converting Raw ... technology can turn raw, heterogeneous data into actionable knowledge ... online webinar will last approximately one hour. , Synopsis: ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2
... NEW YORK, March 1, 2012 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0788386/Global-Biotechnology-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechno The global outlook series ... anecdotes, market briefs, and concise summaries of ...
... 2012  Receptos Inc. today announced that the company is scheduled ... Care Conference at noon EST on Wednesday, March 7, 2012, ... Hasnain, president and chief executive officer, will provide an overview ... programs. "This is an exciting time at ...
... Laboratories, Inc. (OTCBB: UGNE), a leader in the design, ... that the Company,s senior management team will host a ... 8, 2012 at 11 a.m. ET to discuss fourth ... Interested participants and investors may access the conference call ...
Cached Biology Technology:Global Biotechnology Industry 2Global Biotechnology Industry 3Global Biotechnology Industry 4Global Biotechnology Industry 5Global Biotechnology Industry 6Receptos to Present at the Cowen and Company 32nd Annual Health Care Conference 2Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012 2
(Date:4/23/2014)... "playwright" to their resumes in an effort to aid ... ethical issues as genomic science transitions to bedside healthcare, ... , Until now the plays of Karen H. ... and by, their peers and others in the genomics ... With Oxford University Press, publication of the book ...
(Date:4/23/2014)... is available in French and German . ... female? In humans and other mammals, the difference between sexes depends ... is present only in males, where the two sexual chromosomes are ... Y is ultimately responsible for all the morphological and physiological differences ... the case. A very long time ago, the X and Y ...
(Date:4/23/2014)... most in their mid-thirties and forties, face a ... within two decades. "Mutant" protein clusters, long blamed ... been the primary focus of therapies in development ... from Prof. Gerardo Lederkremer and Dr. Julia Leitman ... and Immunology, in collaboration with Prof. Ulrich Hartl ...
Breaking Biology News(10 mins):Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3Male or female? 2Male or female? 3On the defensive 2On the defensive 3
... nanometer and micron size scales could play a key ... improve the reliability, reduce the size and lower the ... by a team of scientists from the Georgia Tech ... the Naval Surface Warfare Center, the highly-uniform copper structures ...
... treat certain cancers and rheumatoid arthritis appears to greatly ... Medicine researchers report in the Journal of Clinical Investigation. ... continue to be observed long after the antibody is ... antibody, rituximab (anti-CD20), depletes B cells. Experimental evidence in ...
... or physical disabilities should not resort to a ... University. Lori Marino, senior lecturer in the Neuroscience ... Lilienfeld, professor in the Department of Psychology, to ... purveyors of what is known as dolphin-assisted therapy ...
Cached Biology News:Unique porous copper structure enables new generation of military micro-detonators 2Unique porous copper structure enables new generation of military micro-detonators 3Cancer and arthritis therapy may be promising treatment for diabetes 2Dolphin 'therapy' a dangerous fad, Emory researchers warn 2Dolphin 'therapy' a dangerous fad, Emory researchers warn 3
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
... designed for use with the ProQuest Two-Hybrid ... contains deletions in the endogenous GAL4 and ... systems. The strain also has leu2 and ... and prey vectors. MaV203 contains three GAL4 ...
Request Info...
Biology Products: